I think we're actually closer than it may sound. I agree that buying Hikma doesn't undo generic entry, and that Hikma being in play increases the odds of settlement or licensing - that part makes sense. Where I still differ is on necessity and timing. With 50%+ market share, Amarin still has leverage and optionality, and I don't see the incentive to pre-emptively cap upside via a royalty or sale path before that leverage is resolved. Settlement can happen without forcing Amarin into a structural endgame.
Market Data 
Markets 
AI
